ArticleScientific reports2026
Reproductive toxicity of a nano-insecticide (chlorpyrifos) on male albino mice.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chlorpyrifos (CPF) is a commonly used organophosphorus insecticide in agriculture, and it is linked to reproductive toxicity in males by disrupting the endocrine system. Most previous studies focus on its traditional form, neglecting its nanoform, which may pose a greater risk due to enhanced bioavailability. Our study evaluated the reproductive toxicity of a nano-emulsion of CPF (CPF-NE) in male albino mice. Mice were divided into four groups (n = 10 per group): a control and three treated groups receiving CPF-NE via oral gavage at doses of 3.79, 7.58, and 15.16 mg/kg body weight daily for 35 days. We assessed gonadosomatic index (GSI), reproductive performance (mating success and fertility rate), sperm parameters, DNA fragmentation, hormonal levels (testosterone, FSH, LH), total antioxidant capacity (TAC), malondialdehyde (MDA), and catalase (CAT). Post-treatment testes were examined histologically. Results showed that CPF-NE significantly decreased GSI (from 0.66 ± 0.02 in controls to 0.31 ± 0.02 in high-dose, p < 0.001), reproductive performance (fertility index dropped to zero at high dose), sperm viability (from 74 ± 1.6% to 43.1 ± 1.7%, p < 0.001), and testosterone (from 4.2 ± 0.3 ng/mL to 1.8 ± 0.2 ng/mL, p < 0.001), while increasing FSH, LH, MDA, and DNA fragmentation. Histopathological findings indicated reduced tubular diameters, decreased epithelial heights, and disrupted testicular structure. In conclusion, CPF-NE adversely affects male fertility by increasing oxidative stress and DNA damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.